4. Conclusions
Candida is essentially an extracellular organism and, as such, Abs against critical antigens for virulence are expected to play a role. This has been dismissed in the light of evidence that cell-mediated immune dysfunctions favor candidiasis. However, this does not exclude any additional or even replacing role of Abs in defined settings. There is now clear experimental evidence that some Abs may indeed be therapeutic; the experiments also suggest that under natural conditions, protective Abs may be obscured by the plethora of irrelevant if not disease-enhancing Abs. The time has now come that not only have Abs been shown to play more than a likely protective role against vaginitis, more importantly, these Abs or their engineered fragments should be used therapeutically. Our findings with protective Abs at the vaginal level may constitute the basis for such a clinical development.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aronson, I.K. and Soltani, K. (1976). Chronic mucocutaneous candidosis: A review. Mycopathologia 60: 17–25.
Beninati, C., Oggioni, M.R., Boccanera, M., Spinosa, M.R., Maggi, T., Conti, S., Magliani W., De Bernardis, F., Teti, G., Cassone, A., Pozzi, G., and Polonelli, L. (2000). Therapy of experimental mucosal candidiasis by engineered human commensal bacteria expressing a microbicidal recombinant anti-idiotype. Nat. Biotechnol. 8: 1060–1064.
Bevan, E.A., Herring, A.J., and Mitchell, D.J. (1973). Preliminary characterization of two species of dsRNA in yeast and their relation-ship to the “Killer” character. Nature 142: 81–86.
Bromuro, C., La Valle, R., Sandini, S., Urbani, F., Ausiello, C.M., Morelli, L., Fe d’Ostiani, C., Romani, L., and Cassone, A. (1998). A 70-kilodalton recombinant heat shock protein of Candida albicans is highly immunogenic and enhances systemic murine candidiasis. Infect. Immun. 66: 2154–2162.
Caesar-TonThat, T.C. and Cutler, J.E. (1997). A monoclonal antibody to Candida albicans enhances mouse neutrophil candidacidal activity. Infect. Immun. 65: 5354–5357.
Calderone, R. and Fonzi, W. (2001). Virulence factors of Candida albicans. Trends Microbiol. 9: 327–335.
Casadevall, A. (1995). Antibody immunity and invasive fungal infections. Infect. Immun. 63: 4211–4218.
Casadevall, A., Cassone, A., Bistoni, F., Cutler, J.E., Magliani, W., Murphy, J.W., Polonelli, L., Romani, L. (1998). Antibody and/or cellmediated immunity, protective mechanisms in fungal disease: An ongoing dilemma or an unnecessary dispute? Med. Mycol. 36(S1): 95–105.
Casanova, M., Martinez, J.P., Chaffin, W.L. (1990). Fab fragments from a monoclonal antibody against a germ tube mannoprotein block the yeast-to mycelium transition in Candida albicans. Infect. Immun. 58: 3810–3812.
Cassone, A. and Torosantucci, A. (1991). Immunological moieties of the cell wall. In R. Prasad (ed.), Candida albicans. Springler-Verlag, Berlin, pp. 89–107.
Cassone, A., Boccanera, M., Adriani, D., Santoni, G., and De Bernardis, F. (1995). Rats clearing a vaginal infection by Candida albicans acquire specific, antibody-mediated resistance to vaginal reinfection. Infect. Immun. 63: 2619–2624.
Cassone, A., Corti, S., De Bernardis, F., and Polonelli, L. (1997). Antibodies killer toxins and antifungal immunoprotection: A lesson from nature? Immunol. Today 18: 163–169.
Cassone, A., De Bernardis, F., Ausiello, C.M., Gomez, M.J., Boccanera, M., La Valle, R., and Torosantucci, A. (1998). Immunogenic and protective Candida albicans constituents. Res. Immunol. 149: 289–299.
Cutler, J. (1991). Putative virulence factors of Candida albicans. Annu. Rev. Microbiol. 45: 187–218.
Cutler, J.E., Granger, B.L., and Han, Y. (2002). Vaccines, antibodies and passive immunity in candidiasis. In R.A. Calderone and R.L. Cihlar (eds), Fungal Pathogenesis. Marcel Dekker, New York, pp. 243–251.
Czerkinnsky, C., Anjuere, F., McGhee, J.R., George-Chandy, A., Holmgren, J., Kieny, M.P., Fujiyashi, K., Mestecky, J.F., Pierrefite-Carle, V., Rask, C., and Sun, J.B. (1999). Mucosal immunity and tolerance: Relevance to vaccine development. Immun. Rev. 170: 197–222.
De Bernardis, F., Agatensi, L., Ross, I.K., Emerson, G.W., Lorenzini, R., Sullivan, P.A., and Cassone, A. (1990). Evidence for a role for secreted aspartate proteinase of Candida albicans in vulvovaginal candidiasis. J. Infect. Dis. 161: 1276–1283.
De Bernardis, F., Cassone, A., Sturtevant, J., and Calderone, R. (1995). Expression of Candida albicans SAP1 and SAP2 in experimental vaginitis. Infect. Immun. 6: 1887–1892.
De Bernardis, F., Boccanera, M., Adriani, D., Spreghini, E., Santoni, G., and Cassone, A. (1997). Protective role of antimannan and antiaspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect. Immun. 65: 3399–3405.
De Bernardis, F., Muhlschlegel, F.A., Cassone, A., and Fonzi, W.A. (1998). The pH of the host niche controls gene expression in and virulence of Candida albicans. Infect. Immun. 66: 3317–3325.
De Bernardis, F., Santoni, G., Boccanera, M., Spreghini, E., Adriani, D., Morelli, L., and Cassone, A. (2000). Local anticandidal immune responses in a rat model of vaginal infection by and protection, Candida albicans. Infect. Immun. 68: 3297–3304.
De Bernardis, F., Boccanera, M., Adriani, D., Girolamo, A., and Cassone, A. (2002). Intravaginal and intranasal immunization are equally effective in inducing vaginal antibodies and conferring protection against vaginal candidiasis. Infect. Immun. 70: 2725–2729.
De Bernardis, F., Boccanera, M., Amantini, C., and Santoni, G. (2004). T and B lymphocytes in mucosal candidiasis. In G. San-Blas and R. Calderone (eds), Pathogenic Fungi: Host Interaction and Emerging Strategies for Control, Caister Academic Press, UK.
Elitsur, Y., Jackman, S., Neace, C., Keerthy, S., Liu, S., Dosescu, J., and Mosheir, J.A. (1998). Human vaginal mucosa Immune system: Characterization and function. Gen. Diagn. Pathol. 143: 271–277.
Fidel, P.L. Jr. and Sobel, J.D. (1996). Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin. Microbiol. Rev. 9: 335–348.
Fidel, P.L. Jr. and Sobel, J.D. (1998). Protective immunity in experimental Candida vaginitis. Res. Immunol. 146: 361–373.
Fidel, P.L. Jr. and Sobel, J.D. (2002). Host defense against vaginal candidiasis. In: R.A. Calderone (ed.), Candida and Candidosis, ASM Press, Washington, pp. 193–209.
Fidel, P.L., Lynch, M.E., and Sobel, J.D. (1993a). Candida-specific Th1-type responsiveness in mice with experimental vaginal candidiasis. Infect. Immun. 61: 4202–4207.
Fidel, P.L., Jr., Lynch, M.E., and Sobel, J.D. (1993b). Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis. Infect. Immun. 61: 1990–1995.
Fidel, P.L. Jr., Lynch, M.E., and Sobel, J.D. (1994). Effects of preinduced Candida-specific systemic cell-mediated immunity on experimental vaginal candidiasis. Infect. Immun. 62: 1032–1038.
Fidel, P.L., Cutright, J.L., and Sobel, J.D. (1995a). Effects of systemic cell-mediated immunity on vaginal candidiasis in mice resistant and susceptible to Candida albicans infections. Infect. Immun. 63: 4191–4194.
Fidel, P.L. Jr., Lynch, M.E., Conaway, D.H., Tait, L., and Sobel, J.D. (1995b). Mice immunized by primary vaginal Candida albicans infection develop acquired vaginal mucosal immunity. Infect. Immun. 63: 547–553.
Fidel, P.L., Lynch, M.E., and Sobel, J.D. (1995c). Circulating CD4 and CD8 T-cells have little impact on host defence against experimental vaginal candidiasis. Infect. Immun. 63: 2403–2408.
Fidel, P.L., Wolf, N.A., and Kukuruga, M.A. (1996). T lymphocytes in the murine vaginal mucosa are phenotypically distinct from those in the periphery. Infect. Immun. 64: 3793–3799.
Fidel, P.L., Ginsburg, K.A., Cutright, J.L., Wolf, N.A., Leaman, D., Dunlops, K., and Sobel, J.D. (1997a). Vaginal-associated immunity in women with recurrent vulvovaginal candidiasis: Evidence for vaginal Th1-type responses following intravaginal challenge with Candida antigen. J. Infect. Dis. 176: 728–739.
Fidel, P.L., Luo, W., Chabain, J., Wolf, N.A., and Vanburen, E. (1997b). Use of cellular depletion analysis to examine circulation of immune effector function between the vagina and the periphery. Infect. Immun. 65: 3939–3943.
Fidel, P.L. Jr., Luo, W., Steele, C., Chabain, J., Baker, M., and Wormley, F. Jr. (1999). Analysis of vaginal cell populations during experimental vaginal candidiasis. Infect. Immun. 67: 3135–3140.
Garcia-Ruiz, J.C., Del Carmen Arilla, M., Regulez, P., Quindos, G., Alvarez, A., and Ponton, J. (1997). Detection of antibodies to Candida albicans germ tubes for diagnosis and therapeutic monitoring of invasive candidiasis inpatients with hematologic malignancies. J. Clin. Microbiol. 35: 3284–3287.
Ghannoum, M.A. and Abu-Elteen, K.H. (1990). Pathogenicity determinant of Candida. Mycoses 33: 265–282.
Greenfield, R.A. (1992). Host defense system interaction with Candida. J. Med. Vet. Mycol. 30: 89–104.
Guyard, C., Dehecq, E., Tissier, J.P., Polonelli, L, Dei-Cas, E., Cailliez, J.C., and Menozzi, F.D. (2002). Involvement of beta-glucan in the wide spectrum antimicrobial activity Williopsis saturnus var mrakii MUCL 41968 killer toxin. Mol. Med. 8: 686–694.
Han, Y., Kanbe, T., Cherniak, R., and Cutler, J. (1997). Biochemical characterization of Candida albicans epitopes that can elicit protective and nonprotective antibodies. Infect. Immun 65: 4100–4107.
Han, Y., Morrison, R.P., and Cutler, J.E. (1998). A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection. Infect. Immun. 66: 5771–5776.
Han, Y., Riesselman, M., and Cutler, J.E. (2000). Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody. Infect. Immun. 68: 1649–1654.
Jones-Carson, J., Vazquez-Torres, A., van der Heyde, T., Warner, T., Wagner, R.D., and Balish, E. (1995). γδ T cell-induced nitric oxide production enhances resistance to mucosal candidiasis. Nat. Med. 6: 552–557.
Kinsman, O.S. and Collard, A.E. (1986). Hormonal factors in vaginal candidiasis in rats. Infect. Immun. 53: 498–504.
Kinsman, O.S., Collard, A.E., and Savage, T.J. (1986). Ketoconazole in experimental vaginal candidosis in rats. Antimicrob. Agents Chemother. 30: 771–773.
Kirkpatrick, C.H., Rich, R.R., and Bennett, J.E. (1971). Chronic mucocutaneous candidiasis: Model-building in cellular immunity. Ann. Intern. Med. 74: 955–978.
Magliani, W., Conti, S., De Bernardis, F., Gerloni, M., Bertolotti, D, Mozzoni, P., Cassone, A., and Polonelli, L. (1997). Therapeutic activity of single chain fragment variable yeast-killer toxin-like candidacidal recombinant antiidiotypic antibodies. Nat. Biotechnol. 15: 155–158.
Magliani, W., Conti, S., De Bernardis, F., Cassone, A., and Polonelli, L. (2002). New immunotherapeutic strategies to control vaginal candidiasis. Trends Mol. Med. 8: 121–126.
Marodi, L. (1997). Local and systemic host defence mechanisms against Candida: Immunopathology of candidal infections. Pediatr. Infect. Dis. 16: 795–801.
McGhee, J.R., Mestecky, J., Elson, C.O., and Kiyono, H. (1989). Regulation of IgA synthesis and immune response by T cells and interleukins. J. Clin. Immun. 9: 175–180.
Mourad, S. and Friedman, L. M. (1961). Active immunization of mice against Candida albicans. Proc. Soc. Exp. Biol. Med. 106: 570–572.
Mourad, S. and Friedman, L. M. (1968). Passive immunization of mice against Candida albicans. Sabouradia 6: 103–105.
Mulero-Marchese, R.D., Blank, K.J., and Siek, T.G. (1998). Genetic basis for protection against experimental vaginal candidiasis by peripheral immunization. J. Infect. Dis. 178: 227–234.
Oggioni, M.R., Beninati, C., Boccanera, M., Medaglini, D., Spinosa, M.R., Maggi, T., Conti, S., Magliani, W., De Bernardis, F., Teti, G., Cassone, A., Pozzi, G., and Polonelli, L. (2001). Recombinant Streptococcus gordonii for mucosal delivery of a scFv microbicidal antibody. Intern. Rev. Immunol. 20: 267–279.
Polonelli, L. and Morace, G. (1986). Re-evaluation of the yeast killer phenmenon. J. Clin. Microbiol. 24: 866–869.
Polonelli, L. and Morace, G. (1987). Production and characterization of yeast killer toxin monoclonal antibodies. J. Clin. Microbiol. 25: 460–462.
Polonelli, L., Conti, S., Gerloni, M., Magliani, W., Chezzi, C., and Morace, G. (1991). Interfaces of the yeast killer phenomenon. Crit. Rev. Microbiol. 18(1): 47–87.
Polonelli, L., Lorenzini, R., De Bernardis, F., Gerloni, M., Conti, S., Morace, G., Magliani, W., and Chezzi, C. (1993). Idiotypic vaccination immunoprotection mediated by anti-idiotypic antibodies with antibiotic activity. Scand. J. Immunol. 37: 105–110.
Polonelli, L., De Bernardis, F., Conti, S., Boccanera, M., Gerloni, M., Morace, G., Magliani, W., Chezzi, C., and Cassone, A. (1994). Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies. J. Immunol. 152: 3175–3182.
Polonelli, L., De Bernardis, F., Conti, S., Boccanera, M., Magliani, W., Gerloni, M., Cantelli, C., and Cassone, A. (1996). Human natural yeast killer toxin-like, candidacidal antibodies. J. Immunol. 156: 1880–1885.
Polonelli, L., De Bernardis, F., Conti, S., Gerloni, M., and Cassone, A. (1997). Yeast killer toxinlike antibodies in experimental and clinical candidiasis. In Y. Shoenfeld, R.C. Kennedy, and S. Ferrone (eds), Idiotypes in Medicine: Autoimmunity, Infection and Cancer. Elsevier Science, Amsterdam, pp. 369–380.
Polonelli, L., Magliani, W., Conti, S., Bracci, L., Lozzi, L., Neri, P., Adriani, D., De Bernardis, F., and Cassone, A. (2003). Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis. Infect. Immun. 71: 6205–6212.
Rogers, T.J. and Balish, E. (1980). Immunity to Candida albicans. Microbiol. Rev. 44: 660–682.
San Millan, R., Ezkurra, P.A., Quindòs, G., Robert, R., Senet, J.M., and Pontòn J. (1996). Effect of monoclonal antibodies directed against Candida albicans cell wall antigens on the adhesion of the fungus to polystyrene. Microbiology 142: 2271–2277.
Santoni, G., Boccanera, M., Adriani, D., Lucciarini, R., Amantini, C., Morrone, S., Cassone, A., and De Bernardis, F. (2002). Immune cell-mediated protection against vaginal candidiasis: Evidence for a mayor role of vaginal CD4+ T cells and possible participation of other local lymphocyte effectors. Infect. Immun. 70: 4791–4797.
Scicchitano, R., Stanisz, A., Ernst, P.B., and Bunenstock, J. (1988). A common mucosal immune system revised. In A.J. Husband (ed.), Migration and Homing of Lymphoid Cells, Vol. 2. CRC Press, Boca Raton, FL, pp. 1–34.
Sobel, J.D. (1989). Pathogenesis of Candida vulvovaginitis. In M.R. Mc Ginnis and M. Borges (eds), Current Topics in Medical Mycology. Springer-Verlag, Stuttgart, pp. 86–108.
Sobel, J.D. (1992). Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin. Infect. Dis. 14: S148–S153.
Steele, C., Ratteree, M., Harrison, R., and Fidel, P.L. Jr. (1999). Differential susceptibility to experimental vaginal candidiasis in macaque. J. Infect. Dis. 180: 802–810.
Tipper, D.J. and Bostian, K.A. (1984). Double-stranded ribonucleic acid killer system in yeasts. Microbiol. Rev. 48: 125–156.
Walker, S.M. and Urbaniak, S.J. (1980). A serum-dependent defect of neutrophil function in chronic mucocutaneous candidiasis. J. Clin. Pathol. 33: 370–372.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
De Bernardis, F., Boccanera, M., Cassone, A. (2005). The Role of Humoral Immunity against Vaginal Candida Infection. In: Fidel, P.L., Huffnagle, G.B. (eds) Fungal Immunology. Springer, Boston, MA. https://doi.org/10.1007/0-387-25445-5_17
Download citation
DOI: https://doi.org/10.1007/0-387-25445-5_17
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-24092-3
Online ISBN: 978-0-387-25445-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)